Ex-Jazz Saks elected to Depomed board
This article was originally published in Scrip
Speciality pharma company Depomed has appointed Jazz Pharmaceuticals' former co-founder Dr Samuel Saks to the company's board of directors. Dr Saks served as Jazz's CEO from 2003-2009.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.